OPKO Health

Update in progress

OPK (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

OPKO Health, Inc. is a multinational healthcare company based in Miami, FL, with operations in the US, Ireland, Chile, Spain, Israel, and Mexico. It has two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001 and MDX2003 (tetra-specific antibodies for solid and hematologic tumors, Phase 1), MDX2004 (trispecific immune modulator), an Epstein–Barr Virus vaccine, Rayaldee, OPK-88006, and NGENLA. The Diagnostics segment offers BioReference lab testing and related services, plus 4Kscore and molecular/genetics testing.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive